Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

MANILA, Philippines — The investments of conglomerate San Miguel Corp. (SMC) for the environment are bearing fruits, making its chairman and CEO Ramon Ang proud of the group’s recent ...

He soon would offer ... Accompanied by a respected team of musicians (Jessé Sadoc, trumpet and flugelhorn; David Feldman, piano; Jefferson Lescowich, acoustic bass), Rio de Janeiro drummer Alfredo ...